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Background/aim: High levels of triglyceride (TG) and fasting blood glucose (FBG) values increase atherosclerosis risk. This study
evaluates the relationship between peripheral artery disease (PAD) severity and complexity, as assessed by TransAtlantic InterSociety
Consensus-II (TASC-II) classification and the triglyceride-glucose (TyG) index.
Materials and methods: A total of 71 consecutive patients with PAD (males 93%, mean age 63.3 ± 9.7), who underwent percutaneous
peripheral intervention were included retrospectively. The patients were divided into two groups according to the angiographically
detected lesions. Those with TASC A-B lesions were included in Group 1, and those with TASC C-D lesions were included in Group 2.
TyG index was calculated as formula: ln[fasting TG (mg/dL) × fasting plasma glucose (mg/dL)/2].
Results: There were 40 patients in Group 1 (90.3% men, with a mean age of 63.6 ± 9.3 years) and 31 patients in Group 2 (96.8% men,
with a mean age of 62.0 ± 8.6 years). In the majority of patients in both groups, the target vessels are iliac arteries and femoral arteries.
In Group 2, platelet count and TyG index were significantly high, according to Group 1. The TyG index was significantly correlated with
TASC-II, Rutherford category, HbA1c, and HDL-C.
Conclusion: In this present study, we showed that the TyG index was an independent predictor of peripheral artery disease complexity,
according to TASC-II classification, for the first time in the literature.
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1. Introduction
Peripheral arterial disease (PAD) is an essential cause of
cardiovascular morbidity and mortality worldwide, and
its frequency is gradually increasing. Although lower
extremity peripheral artery disease is more common in
men, its incidence also increases in women over 50 years.
The presentations of PAD can differ from asymptomatic
to intermittent claudication, critical limb ischemia (CLI),
or acute limb ischemia (ALI) [1]. Since the underlying
pathology is atherosclerosis, its association with ischemic
heart diseases and cerebrovascular diseases is common [2].
Risk factors for atherosclerosis, for instance, hypertension
(HT), diabetes mellitus (DM), smoking, hyperlipidemia
(HL), and obesity, are common among patients with
PAD [3]. PAD is associated with an increased risk of
cardiovascular and all-cause mortality as well [4].
It is remarkably relevant to define the complexity of the
PAD to make an early diagnosis and design the treatment
strategy in patients with clinical suspicion. TransAtlantic
InterSociety Consensus-II (TASC-II) classification is

a consensus definition that is used to evaluate PAD
concerning the anatomic distribution of lesions. This
anatomical classification provides the most appropriate
revascularization strategy (endovascular and surgical) and
treatment decisions based on the complexity, number, and
location of the lesions [5].
High levels of triglyceride (TG) and fasting blood glucose
(FBG) are the most critical risk factors for cardiovascular
disease (CVD) [6]. The combination of both indicators,
triglyceride glucose (TyG) index, is a novel marker, which
has been verified to have a high sensitivity and specificity in
identifying metabolic syndrome [7]. Furthermore, studies
have shown an association of the TyG index with the
incidence of CVD [8], stroke [9], carotid atherosclerosis
[10], and CAD incidence [11]. Unfortunately, there is
currently insufficient data on whether the TyG index
predicts the severity and complexity of peripheral artery
disease. Therefore, in our study, we aimed to evaluate
the relationship between PAD severity and complexity
evaluated by TASC-II classification and TyG ratio.
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2. Materials and methods
A total of 71 consecutive patients with PAD (males 93%,
mean age 63.3 ± 9.7), who underwent percutaneous
peripheral intervention in our tertiary care center were
included retrospectively. All demographic data (age, sex),
comorbidities (DM, HT, hyperlipidemia, smoking, atrial
fibrillation, CAD), physical conditions, symptoms, and
routine blood tests were obtained from hospital records.
Classification of PAD was performed due to TASC II
guidelines. All patients were divided into two groups due
to the severity of the lesions detected angiographically.
Those with TASC A-B lesions were included in Group 1,
and those with TASC C-D lesions were included in Group
2. According to the current literature, Rutherford and
Fontaine’s classification was obtained for each patient [12].
Peripheral blood samples were obtained from the
antecubital vein after at least 12-h fasting for detection of
complete blood count (CBC), total serum cholesterol (TC),
triglycerides (TGs), HDL-cholesterol, and low-density
lipoprotein (LDL) cholesterol and plasma glucose (Sysmex
K-1000, Sysmex Corporation, Kobe, Japan) on admission.
All routine biochemical analyses were performed using an
auto-analyzer (Roche Diagnostic Modular Systems, Tokyo,
Japan). TyG index was calculated as formula: ln[fasting TG
(mg/dL) × fasting plasma glucose (mg/dL)/2]. The local
ethics committee approved this study, and individual
informed consent was obtained from all patients.
2.1. Statistical analysis
Data are expressed as percentages or mean ± standard
deviation. Continuous variables were checked for normal
distribution assumptions using Kolmogorov–Smirnov
test. Continuous variables were presented as the mean ±
standard deviation and compared using t-tests (for data
complying with a normal distribution) or Mann–Whitney
U-tests (for data complying with nonnormal distribution).
Categorical variables were presented as frequencies and
percentages and compared using Pearson’s and Fisher’s
exact test the chi-square test. Correlation analysis was
performed using Pearson or Spearman tests. All analyses
were performed using SPSS for Windows version 22.0
(IBM Corp., Armonk, NY, USA). A P-value <0.05 was
considered as signiﬁcant.
3. Results
The
demographic,
laboratory
and
procedural
characteristics of patients were categorized by TASC-II
classification. There were 40 patients in Group 1 (90.3%
men, with a mean age of 63.6 ± 9.3 years) and 31 patients in
Group 2 (96.8% men, with a mean age of 62.0 ± 8.6 years).
Table 1 shows the comparison of clinical characteristics
between the two groups. While most of the patients in
both groups presented with intermittent claudication
symptoms, 9.9% of all patients consulted with rest pain.
As expected, walking distance without claudication was
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increased in group 1 (99.4 ± 67.8 vs. 61.7 ± 53.6, P: 0.018).
32.5% of patients in group 1 previously had a history of
CABG and was statistically significantly more common
in patients than group 2 (P: 0.008). According to the
Fontaine and Rutherford classification, patients in Group
2 were more severely symptomatic (P: 0.004 vs. P: 0.006,
respectively).
In the majority of patients in both groups, the target
vessels were iliac arteries and femoral arteries. The
vast majority of patients in both groups were treated
with percutaneous transluminal angioplasty and stent
implantation. There was no difference between the two
groups in terms of stent type, mean balloon diameter,
mean balloon length, mean stent diameter, and mean stent
length.
The laboratory variables of all patients are presented in
Table 2. The groups were similar in terms of hemoglobin,
serum glucose, HbA1c, creatinine, C-reactive protein,
total cholesterol, triglyceride, high-density lipoprotein
cholesterol (HDL-C), and low-density lipoprotein
cholesterol (LDL-C) values. In Group 2, platelet count and
TyG index were significantly high, according to Group 1
(P: 0.035, P: 0.011, respectively).
Correlation analysis was used to examine the
relationship between the TyG index and clinical variables.
The TyG index was significantly correlated with TASC-II,
Rutherford category, HbA1c, and HDL-C (Table 3).
4. Discussion
This is the first study to analyze the association between the
TyG index and PAD severity to the best of our knowledge.
The main findings are as follows: (1) the TyG index is
an independent predictor of peripheral artery disease
complexity and (2) the TyG index is correlated with TASCII classification, Rutherford category, and also HDL-C.
The TyG index is a composite indicator consisting of
TG and fasting blood glucose (FBG), and is a useful marker
of insulin resistance (IR) and a predictor of type 2 diabetes
mellitus (T2DM) [13]. Afterward, several studies were
managed and found a positive relationship between the
TyG index and CVD. Irace et al. evaluated the relationship
between carotid atherosclerosis and the TyG index in
two different groups and gained positive results [10].
Besides, a study involving 4319 patients showed that the
TyG index was significantly associated with the presence
of coronary calcification [14]. Several prospective studies
have been conducted on the link between the TyG index
and cardiovascular events (CVEs). Vega et al. investigated
the relationship between TyG index and cardiovascular
mortality, CAD or CVD in 39,447 men and showed that
the TyG index does not predict CVD mortality, but this
study does not reflect the general population [15]. In
another study, higher levels of the TyG index in 5014
healthy individuals were associated with an increased
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Table 1. Baseline characteristics of the patients.
Parameters

Group 1
n = 40

Group 2
n = 31

P value

Age (years)

63.6 ± 9.3

62.0 ± 8.6

0.465

Male n (%)

36 (95.0)

28 (90.3)

0.445

Symptom n (%)
- Intermittent Claudication
- Rest pain
- Trophic Changes

35 (87.5)
1 (2.5)
4 (10.0)

24 (77.4)
4 (12.9)
3 (9.7)

Walking distance without claudication (mt)

99.4 ± 67.8

61.7 ± 53.6

0.018

HT n (%)

35 (87.5)

25 (80.6)

0.429

HL n (%)

20 (50.0)

15 (48.4)

0.324

Current smoker n (%)

19 (47.5)

15 (48.4)

0.288

DM n (%)

17 (52.5)

21 (67.7)

0.079

AF n (%)

1 (2.5)

3 (9.7)

0.193

Previous PCI n (%)

18 (45.0)

10 (32.3)

0.276

Previous CABG n (%)

13 (32.5)

2 (6.5)

0.008

Previous peripheral intervention n (%)

9 (22.5)

2 (6.5)

0.061

Stenosis (%)

92.6 ± 7.5

95.7 ± 6.7

0.094

CAD n (%)
- Normal
- Nonobstructive
- 1 vessel disease
- 2 vessel disease
- 3 vessel disease

1 (2.5)
6 (15.0)
12 (30.0)
18 (45.0)
3 (7.5)

1 (3.2)
5 (16.1)
10 (32.3)
12 (38.7)
3 (9.7)

Rutherford category n (%)
-2
-3
-4
-5

14 (38.9)
17 (47.2)
4 (11.1)
1 (2.8)

2 (6.9)
14 (48.3)
6 (20.7)
7 (27.1)

Fontaine grade n (%)
-I
- IIA
- IIB
- III
- IV

1 (2.8)
6 (16.7)
15 (41.7)
13 (36.1)
1 (2.8)

0
1 (3.4)
5 (17.2)
15 (51.7)
8 (27.6)

Target vessel n (%)
- CIA
- SFA
- Popliteal
- Below the knee

16 (40.0)
17 (42.5)
5 (12.5)
2 (5)

14 (45.1)
13 (41.9)
2 (6.4)
2 (6.4)

Peripheral intervention n (%)
- PTA
- Stent
- PTA+Stent
- Drug eluting balloon

11 (28.2)
7 (17.9)
21 (53.8)
11 (28.2)

6 (22.2)
2 (7.4)
19 (70.4)
5 (18.5)

Type of stent n (%)
- Self-expandable
- Balloon expandable

15 (55.6)
12 (44.4)

11 (52.4)
10 (47.6)

0.287

0.987

0.004

0.006

0.442

0.326

0.827
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Table 1. (Continued).
Mean balloon diameter mm

5.2 ± 1.3

4.9 ± 1.7

0.503

Mean balloon length mm

62.6 ± 43.5

63.8 ± 37.0

0.917

Mean stent diameter mm

7.4 ± 1.1

7.2 ± 1.3

0.509

Mean stent length mm

56.1 ± 36.8

59.2 ± 33.8

0.714

LVEF (%)

51.3 ± 13.8

50.3 ± 14.6

0.776

LVEDD (cm)

5.0 ± 0.8

4.8 ± 0.4

0.286

LVESD (cm)

3.3 ± 1.0

3.2 ± 0.6

0.870

LA (cm)

4.1 ± 0.4

3.7 ± 0.4

<0.001

sPAP (mmHg)

22.5 ± 12.8

25.3 ± 16.8

0.467

HT: Hypertension; HL: Hyperlipidemia; DM: Diabetes mellitus; AF: Atrial fibrillation; PCI: Percutaneous coronary
intervention, CABG: Coronary artery bypass grafting, CAD: Coronary artery disease, CIA: Common iliac artery,
SFA: Superficial femoral artery; PTA: Percutaneous transluminal angioplasty; LVEF: Left ventricular ejection fraction,
LVEDD: Left ventricular end diastolic diameter, LVESD: Left ventricular end systolic diameter, LA: Left atrium, sPAP:
Systolic pulmonary artery pressure.
Table 2. Laboratory variables of the patients.
Parameters

All Patients
n = 71

Group 1
n = 40

Group 2
n = 31

P value

Serum glucose (mg/dL)

127.8 ± 69.0

113.5 ± 55.5

142.9 ± 80.6

0.077

HbA1c (%)

6.55 ± 1.46

6.39 ± 1.01

6.89 ± 1.98

0.480

Serum creatinine (mg/dL)

1.1 ± 0.8

1.0 ± 0.6

1.2 ± 0.9

0.288

Total cholesterol (mg/dL)

191.3 ± 43.7

191.1 ± 46.6

184.8 ± 39.1

0.563

Triglyceride (mg/dL)

182.4 ± 106.5

160.3 ± 62.9

212.2 ± 147.8

0.052

LDL cholesterol (mg/dL)

116.0 ± 36.3

111.1 ± 37.7

116.2 ± 32.8

0.565

HDL cholesterol (mg/dL)

39.7 ± 12.1

38.7 ± 11.0

40.3 ± 14.4

0.599

Hemoglobin g/dL

14.5 ± 2.0

14.5 ± 2.1

14.8 ± 1.9

0.428

Platelet ×109 /L

239.5 ± 59.7

225.2 ± 58.3

255.9 ± 60.2

0.035

TyG

73575.0 ± 13069.1

9019.8 ± 6096.8

18209.4 ± 20873.9

0.011

HbA1c: Glycated hemoglobin, LDL: Low-density lipoprotein, HDL: High-density lipoprotein, TyG: Triglyceride-glucose
index.

risk of developing CVD [16]. In another observational
study, Mao et al. showed that the TyG index might be an
independent predictor of coronary artery disease severity
and cardiovascular outcomes in acute coronary syndrome
[16]. But there is no study about the relationship between
TyG index and PAD severity. Currently, only a few studies
have been reported on the association between the TyG
index and CVD; however, there is no study investigating
its relationship with peripheral artery disease complexity.
The role of blood lipid parameters in the development
of atherosclerotic PAD is crucial. Epidemiological studies
have shown that dyslipidemia alone is sufficient for
atherosclerosis development, even without other risk
factors [17]. In current studies, Kim et al. [14], and Lee

1220

et al. [18] reported that the TyG index was linked with
arterial stiffness and coronary artery calcification in
Korean adults. Another abovementioned study [16] found
that the TyG index was a predictor of hypertension in a
Chinese population. All these studies implied that the TyG
index could act as a biomarker for arterial diseases, and the
IR predicted by the TyG index may have been involved in
vascular remodeling and atherogenesis.
But despite all these studies, the relationship between
the TyG index and peripheral artery disease complexity
remains unclear. The TyG index formula consists of
a combination of TG and fasting blood glucose. TG’s
relationship with the risk of CVD is still controversial,
but a new set of evidence has proved that TG and TG-rich
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Table 3. Correlation between the TyG index and clinical variables.
Parameters

r value

P value

Stenosis

0.090

0.445

Age

-0.079

0.495

Walking distance without claudication

-0.168

0.178

TASC-II

0.302

0.011

Rutherford category

0.249

0.047

Fontaine grade

0.199

0.115

HbA1c

0.647

<0.001

HDL-C

-0.315

0.007

HbA1c: Glycated hemoglobin, HDL: High-density lipoprotein,
TyG: Triglyceride-glucose index.

lipoproteins are the causative factors of CVD [19]. The
concurrency of hypertriglyceridemia (HTG) promotes
the formation of small dense LDL particles [20]. Although
most studies have evaluated TG’s risk of CVD in HTG
patients only, several studies have shown that high-normal
range plasma TG predicts CVEs. Glucose disorder is
another CVD risk factor that often coexists with HTG.
Evaluating these two parameters together increases their
CVE predictive power. Since atherosclerosis is a common
etiopathogenesis for CVD and PAD, the TyG index’s
analysis was decided in our study.
The TASC-II guidelines were published in 2007 and
involved a change of the original TASC classification for
PAD, focusing on the aortoiliac and femoropopliteal regions.
TASC-II also aimed to guide treatment decisions correlating
to the optimal revascularization strategy (endovascular vs.
surgical) according to the patient’s anatomic and clinical

status. Generally, this revision issued in the reclassification
of more complex anatomies into less severe categories of
the TASC classification (e.g., TASC C lesions reclassified as
TASC B lesions with an associated alteration from surgical
to endovascular treatment). TASC A and B lesions were
still suggested for primary endovascular revascularization,
TASC D lesions for surgical revascularization, and TASC
C lesions for surgical revascularization in patients with
proper perioperative risk and accessible conduit [21].
According to recent studies, the increase in TG/HDL ratio,
also known as the atherogenic index, is a significant risk
factor for cardiovascular diseases and metabolic syndrome
[22]. Mesut et al. [23] showed that the TG/HDL-C ratio
could predict the angiographic complexity of peripheral
artery disease according to the TASC II classification.
Based on these data, it is not surprising to predict the
peripheral artery disease complexity with the TyG index,
as we showed in our study.
There are several limitations to our study. First of all,
this study is a single-center retrospective trial, and the
sample size is small. Another limitation of the study is the
absence of a control group. Since our center is a reference
center, as long-term follow-up data is limited, the effect
on mortality is uncertain. Further multicenter prospective
studies may generate more relevant results on this issue.
In this present study, we showed that the TyG index
was an independent predictor of peripheral artery disease
complexity, according to TASC-II classification, for the
first time in the literature. TyG index is a simple parameter
that can be easily obtained from routine biochemical
parameters, and large-scale studies are needed to evaluate
whether it predicts PAD complexity.
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